Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production

Fig. 5

Covalently bound CC-99677 resulted in a cumulative increase in MK2 occupancy with daily dosing. CC-99677 target engagement with MK2 binding measured as a percentage change from baseline with the last dose on day 14. Measurements in PBMCs isolated from the whole blood of healthy subjects dosed with CC-99677 in MAD study with streptavidin mass shift assay. Data depicted as means with standard error of the means. MAD, multiple ascending dose; MK2, mitogen-activated protein kinase-activated protein kinase-2; PBMC, peripheral blood mononuclear cell

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us